Here, we tested a new immunotherapy strategy that combines intranodal administration of the DRibble vaccine with an anti-OX40 co-stimulatory antibody in a murine mammary carcinoma model and found that this combination dramatically enhanced T-cell priming and anti-tumor efficacy of the DRibble vaccine. Here, TNFRSF4 is linked to breast carcinoma.